Burren Capital Advisors Ltd Purchases Shares of 23,044 Amedisys, Inc. (NASDAQ:AMED)

Burren Capital Advisors Ltd acquired a new position in Amedisys, Inc. (NASDAQ:AMED) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 23,044 shares of the health services provider’s stock, valued at approximately $2,092,000. Amedisys comprises 10.1% of Burren Capital Advisors Ltd’s investment portfolio, making the stock its 3rd biggest holding. Burren Capital Advisors Ltd owned 0.07% of Amedisys as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of the stock. Pacer Advisors Inc. boosted its holdings in Amedisys by 11,621.9% during the fourth quarter. Pacer Advisors Inc. now owns 558,197 shares of the health services provider’s stock worth $50,679,000 after purchasing an additional 553,435 shares during the last quarter. Polar Asset Management Partners Inc. bought a new position in shares of Amedisys during the 3rd quarter worth approximately $28,953,000. Verition Fund Management LLC boosted its stake in shares of Amedisys by 608.1% in the 3rd quarter. Verition Fund Management LLC now owns 114,774 shares of the health services provider’s stock worth $11,077,000 after buying an additional 98,565 shares during the last quarter. Westchester Capital Management LLC grew its holdings in shares of Amedisys by 9.5% in the third quarter. Westchester Capital Management LLC now owns 1,118,802 shares of the health services provider’s stock valued at $107,976,000 after acquiring an additional 97,476 shares in the last quarter. Finally, Calamos Advisors LLC increased its position in shares of Amedisys by 22.7% during the fourth quarter. Calamos Advisors LLC now owns 487,444 shares of the health services provider’s stock valued at $44,255,000 after acquiring an additional 90,097 shares during the last quarter. Institutional investors own 94.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Stephens reissued an “equal weight” rating and issued a $101.00 price objective on shares of Amedisys in a research report on Tuesday. Five research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, Amedisys has an average rating of “Hold” and an average price target of $100.75.

Amedisys Trading Up 0.2 %

Shares of AMED stock opened at $92.37 on Friday. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.05. The firm has a market cap of $3.03 billion, a P/E ratio of 36.65, a PEG ratio of 1.78 and a beta of 0.73. The company has a 50 day moving average of $91.95 and a 200-day moving average of $93.04. Amedisys, Inc. has a 12-month low of $82.15 and a 12-month high of $98.95.

Amedisys (NASDAQ:AMED) last announced its quarterly earnings data on Wednesday, February 26th. The health services provider reported $0.96 earnings per share for the quarter, missing the consensus estimate of $1.05 by ($0.09). The firm had revenue of $598.05 million for the quarter, compared to the consensus estimate of $602.38 million. Amedisys had a net margin of 3.57% and a return on equity of 12.20%. Sell-side analysts anticipate that Amedisys, Inc. will post 4.4 earnings per share for the current year.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.